肺癌治療市場規模、佔有率、成長分析、按癌症類型、按地區分類 - 產業預測，2024-2031 年

2022年全球肺癌治療市場規模約322億美元，預測期間（2024-2031年）複合年成長率為13.2%，從2023年的約364億美元上升至2031年的868億美元預計將達到10億美元。

由於肺癌發病率上升、醫療技術進步以及人們對癌症早期檢測的認知不斷增強，全球肺癌治療市場正在經歷強勁成長。人口老化、生活方式改變和吸煙盛行等多種因素導致肺癌患者數量增加，對有效治療解決方案的需求不斷增加。透過引入標靶治療、免疫療法和個人化醫療等創新療法，市場正在不斷擴大，這些療法在改善患者治療效果方面顯示出了希望。該市場的主要企業正致力於擴大產品平臺並獲得新藥核准，以滿足不斷成長的需求。生物標記的使用、基因檢測的增加以及基因療法等新治療方法的開發正在重塑肺癌治療的模式。此外，製藥公司和研究機構之間的合作正在推動新治療方法的研究，並擴大各個地區獲得先進療法的機會。然而，高昂的治療成本、嚴格的監管以及治療副作用的風險繼續對市場成長構成挑戰。按地區分類，由於醫療保健支出高、基礎設施先進以及大型製藥公司的存在，北美佔據了很大的市場佔有率。然而，由於醫療保健服務的改善和癌症研究投資的增加，亞太地區的新興經濟體正在經歷快速成長。在治療方法創新、改進的診斷方法和活性化宣導活動的支持下，該市場預計將保持其成長軌跡，以促進早期診斷和治療依從性。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 監管分析
• 專利分析
• 價格分析
• 案例研究分析
• 技術分析

肺癌治療市場：依治療分類

• 市場概況
• 標靶治療
  • Bevacizumab
  • Dabrafenib/曲美替尼
  • Erlotinib
  • Osimertinib
  • 其他
• 免疫療法
  • Durvalumab
  • 納武單抗
  • Atezolizumab
  • Pembrolizumab
• 化療

肺癌治療市場：依癌症類型分類

• 市場概況
• 非小細胞肺癌（NSCLC）
• 小細胞肺癌（SCLC）

肺癌治療市場：依分銷管道分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 其他

肺癌治療市場規模：依地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Genentech（F. Hoffmann-La Roche Ltd）
• Eli Lilly and Company
• Celgene Corporation
• AstraZeneca
• Pfizer Inc.
• Sanofi
• Novartis AG
• Astellas Pharma Inc.
• Bristol Myers Squibb
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Millennium Pharmaceuticals, Inc.（Takeda）
• Merck Sharp & Dohme Corp.
• Eisai Co., Ltd.
• Johnson & Johnson
• Bayer AG
• GlaxoSmithKline plc
• Amgen Inc.
• Spectrum Pharmaceuticals, Inc.

Global Lung Cancer Therapeutics Market size was valued at around 32.2 billion in 2022 and is expected to rise from USD 36.4 billion in 2023 to reach a value of USD 86.8 billion by 2031, at a CAGR of 13.2% over the forecast period (2024-2031).

The global lung cancer therapeutics market has been experiencing robust growth due to the rising incidence of lung cancer, advances in medical technology, and increasing awareness regarding early cancer detection. A combination of factors, including an aging population, lifestyle changes, and the prevalence of smoking, has contributed to the increased number of lung cancer cases, driving the demand for effective therapeutic solutions. The market has expanded through the introduction of innovative therapies such as targeted treatments, immunotherapies, and personalized medicines, which have shown promise in improving patient outcomes. Key players in the market are focusing on enhancing their product pipelines and securing regulatory approvals for new drugs to cater to the growing demand. The increasing use of biomarkers, genetic testing, and the development of new treatment modalities, such as gene therapy, are reshaping the landscape of lung cancer treatment. Moreover, collaborations between pharmaceutical companies and research institutions are driving research into novel treatments and expanding access to advanced therapies across different regions. However, the high cost of treatment, stringent regulatory frameworks, and the risk of adverse effects from therapies continue to challenge market growth. Geographically, North America holds a significant market share, driven by high healthcare expenditure, advanced infrastructure, and the presence of major pharmaceutical companies. However, emerging economies in Asia-Pacific are witnessing rapid growth due to improving healthcare access and growing investments in cancer research. The market is expected to continue its growth trajectory, supported by ongoing innovation in treatment methods, improved diagnostics, and increasing awareness campaigns promoting early diagnosis and treatment adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Therapeutics Market Segmental Analysis

Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Distribution Channel, and region. Based on Therapy, the market is segmented into Targeted Therapy (Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib, Others), Immunotherapy (Durvalumab, Nivolumab, Atezolizumab, Pembrolizumab), Chemotherapy. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC). Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Lung Cancer Therapeutics Market

One of the primary drivers of the lung cancer therapeutics market is the rapid advancement in immunotherapy treatments. Immunotherapies, such as immune checkpoint inhibitors (e.g., Keytruda and Opdivo), have revolutionized the approach to treating non-small cell lung cancer (NSCLC) by harnessing the body's immune system to target and eliminate cancer cells. These treatments have demonstrated higher efficacy and longer survival rates compared to traditional chemotherapies. The success of immunotherapy in clinical trials has led to its increasing adoption in treatment regimens, especially for patients with advanced or metastatic lung cancer. Furthermore, ongoing research is exploring combination therapies, where immunotherapy is paired with chemotherapy or targeted therapy to enhance treatment efficacy. The growing acceptance of immunotherapy is supported by regulatory approvals and healthcare providers' recognition of its potential to offer more personalized, effective treatments. As more breakthroughs emerge, the global lung cancer therapeutics market is set to benefit from this continued momentum.

Restraints in the Global Lung Cancer Therapeutics Market

A significant restraint in the global lung cancer therapeutics market is the exorbitant cost of advanced treatments, particularly immunotherapies and targeted therapies. While these innovative therapies offer significant benefits in terms of improved patient outcomes, their high price tags make them inaccessible to a large portion of the population, especially in low- and middle-income countries. The cost of treatment can run into tens of thousands of dollars per cycle, placing a substantial financial burden on both healthcare systems and patients. Even in developed countries, where healthcare insurance may cover some of the expenses, out-of-pocket costs can still be prohibitive for many patients. The lack of affordable options exacerbates disparities in access to life-saving treatments, making cost a major barrier to market expansion. Additionally, the need for prolonged therapy in some cases further drives up overall treatment costs, limiting the broader adoption of advanced therapeutics and impeding the market's growth potential.

Market Trends of the Global Lung Cancer Therapeutics Market

An emerging trend in the lung cancer therapeutics market is the increasing use of biomarker-driven therapies, which are designed based on specific genetic and molecular characteristics of a patient's tumor. Biomarkers such as EGFR mutations, ALK rearrangements, and PD-L1 expression have become pivotal in guiding treatment decisions, particularly in the case of targeted therapies and immunotherapies. Personalized medicine, driven by biomarker identification, allows for the development of treatments tailored to the individual genetic profiles of patients, improving the chances of treatment success and minimizing adverse effects. This trend is further supported by advances in diagnostic technologies that enable quicker and more accurate biomarker detection. As pharmaceutical companies and research institutions continue to invest in biomarker-based research, the market is witnessing a shift toward more precise, individualized treatment approaches. This trend is expected to gain momentum as regulatory bodies approve more therapies linked to specific biomarkers, broadening the therapeutic landscape for lung cancer patients.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Patent Analysis
• Pricing Analysis
• Case Study Analysis
• Technology Analysis

Lung Cancer Therapeutics Market, By Therapy

• Market Overview
• Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
• Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
• Chemotherapy

Lung Cancer Therapeutics Market, By Cancer Type

• Market Overview
• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)

Lung Cancer Therapeutics Market, By Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Lung Cancer Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Genentech (F. Hoffmann-La Roche Ltd)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Millennium Pharmaceuticals, Inc. (Takeda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Sharp & Dohme Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments